Continued azacitidine therapy beyond time of first response improves quality of response in patients with higher‐risk myelodysplastic syndromes
Open Access
- 10 January 2011
- Vol. 117 (12), 2697-2702
- https://doi.org/10.1002/cncr.25774
Abstract
BACKGROUND: In the AZA‐001 trial, azacitidine (75 mg/m2/d subcutaneously for Days 1‐7 of every 28‐day cycle) demonstrated improved survival compared with conventional care regimens in patients with International Prognostic Scoring System‐defined intermediate‐2‐ or high‐risk myelodysplastic syndrome and World Health Organization‐defined acute myeloid leukemia with 20% to 30% bone marrow blasts. METHODS: This secondary analysis of the AZA‐001 phase 3 study evaluated the time to first response and the potential benefit of continued azacitidine treatment beyond first response in responders. RESULTS: Overall, 91 of 179 patients achieved a response to azacitidine; responding patients received a median of 14 treatment cycles (range, 2‐30). Median time to first response was 2 cycles (range, 1‐16). Although 91% of first responses occurred by 6 cycles, continued azacitidine improved response category in 48% of patients. Best response was achieved by 92% of responders by 12 cycles. Median time from first response to best response was 3.5 cycles (95% confidence interval [CI], 3.0‐6.0) in 30 patients who ultimately achieved a complete response, and 3.0 cycles (95% CI, 1.0‐3.0) in 21 patients who achieved a partial response. CONCLUSIONS: Continued azacitidine therapy in responders was associated with a quantitative increase in response to a higher response category in 48% of patients, and therefore may enhance clinical benefit in patients with higher‐risk MDS. Cancer 2011. © 2011 American Cancer Society.Keywords
This publication has 21 references indexed in Scilit:
- Modes of action of the DNA methyltransferase inhibitors azacytidine and decitabineInternational Journal of Cancer, 2008
- Hypomethylation and apoptosis in 5-azacytidine–treated myeloid cellsExperimental Hematology, 2008
- Allogeneic Stem Cell Transplantation for Myelodysplastic SyndromeSeminars in Hematology, 2008
- Further Analysis of Trials With Azacitidine in Patients With Myelodysplastic Syndrome: Studies 8421, 8921, and 9221 by the Cancer and Leukemia Group BJournal of Clinical Oncology, 2006
- Combined DNA Methyltransferase and Histone Deacetylase Inhibition in the Treatment of Myeloid NeoplasmsCancer Research, 2006
- Impact of Azacytidine on the Quality of Life of Patients With Myelodysplastic Syndrome Treated in a Randomized Phase III Trial: A Cancer and Leukemia Group B StudyJournal of Clinical Oncology, 2002
- Randomized Controlled Trial of Azacitidine in Patients With the Myelodysplastic Syndrome: A Study of the Cancer and Leukemia Group BJournal of Clinical Oncology, 2002
- Proposals for the classification of the myelodysplastic syndromesBritish Journal of Haematology, 1982
- Multiple new phenotypes induced in and 3T3 cells treated with 5-azacytidineCell, 1979
- Nonparametric Estimation from Incomplete ObservationsJournal of the American Statistical Association, 1958